Question:
You are tasked with answering the user's question using the provided context, which includes financial statements (Income Statements, Balance Sheets, and Cash Flow Statements) and financial news articles in multiple languages (English, Chinese, Japanese, Spanish, and Greek). Please provide a detailed and well-supported answer based on the information available. Limit your response to 100 words or fewer. If you cannot answer the question or if no relevant evidence is found, write “None”.

Answer Format:
Answer: {Answer using the financial statement.}
News Evidence: {Verify your answer using quote(s) from the financial news. Write “None” if no news evidence is available.}
Context:
Financial Statements:
| Column 1                                                                                | Column 2   | Column 3      | Column 4   | Column 5          | Column 6   | Column 7   | Column 8   | Column 9   | Column 10   | Column 11   | Column 12   | Column 13   | Column 14   | Column 15   |
|:---------------------------------------------------------------------------------------------------|:-----------|:--------------|:-----------|:------------------|:-----------|:-----------|:-----------|:-----------|:------------|:------------|:------------|:------------|:------------|:------------|
|                                                                                |            |               |            |                   |            |            |            |            |             |             |             |             |             |             |
|                                                                                |            | June 30, 2024 |            | December 31, 2023 |            |            |            |            |             |             |             |             |             |             |
| Assets                                                                                |            |               |            |                   |            |            |            |            |             |             |             |             |             |             |
| Current assets:                                                                                |            |               |            |                   |            |            |            |            |             |             |             |             |             |             |
| Cash and cash equivalents (Note 4)                                                                 |            | $24,878       |            | 21,859            |            |            |            |            |             |             |             |             |             |             |
|                                                                                |            |               |            |                   |            |            |            |            |             |             |             |             |             |             |
| Marketable securities                                                                              |            | 597           |            | 1,068             |            |            |            |            |             |             |             |             |             |             |
| Accounts receivable, trade, less allowances $161(2023, $166)                                       |            | 15,794        |            | 14,873            |            |            |            |            |             |             |             |             |             |             |
| Inventories (Note 2)                                                                               |            | 12,169        |            | 11,181            |            |            |            |            |             |             |             |             |             |             |
| Prepaid expenses and other                                                                         |            | 4,379         |            | 4,514             |            |            |            |            |             |             |             |             |             |             |
|                                                                                |            |               |            |                   |            |            |            |            |             |             |             |             |             |             |
| Total current assets                                                                               |            | 57,817        |            | 53,495            |            |            |            |            |             |             |             |             |             |             |
| Property, plant and equipment at cost                                                              |            | 48,035        |            | 47,776            |            |            |            |            |             |             |             |             |             |             |
| Less: accumulated depreciation                                                                     |            | (28,287)      |            | (27,878)          |            |            |            |            |             |             |             |             |             |             |
| Property, plant and equipment, net                                                                 |            | 19,748        |            | 19,898            |            |            |            |            |             |             |             |             |             |             |
| Intangible assets, net (Note 3)                                                                    |            | 39,725        |            | 34,175            |            |            |            |            |             |             |             |             |             |             |
| Goodwill (Note 3)                                                                                |            | 44,250        |            | 36,558            |            |            |            |            |             |             |             |             |             |             |
| Deferred taxes on income (Note 5)                                                                  |            | 9,004         |            | 9,279             |            |            |            |            |             |             |             |             |             |             |
| Other assets                                                                                |            | 10,544        |            | 14,153            |            |            |            |            |             |             |             |             |             |             |
|                                                                                |            |               |            |                   |            |            |            |            |             |             |             |             |             |             |
| Total assets                                                                                |            | $181,088      |            | 167,558           |            |            |            |            |             |             |             |             |             |             |
| Liabilities and shareholders’ equity                                                               |            |               |            |                   |            |            |            |            |             |             |             |             |             |             |
| Current liabilities:                                                                               |            |               |            |                   |            |            |            |            |             |             |             |             |             |             |
| Loans and notes payable                                                                            |            | $9,855        |            | 3,451             |            |            |            |            |             |             |             |             |             |             |
| Accounts payable                                                                                |            | 8,848         |            | 9,632             |            |            |            |            |             |             |             |             |             |             |
| Accrued liabilities                                                                                |            | 10,539        |            | 10,212            |            |            |            |            |             |             |             |             |             |             |
| Accrued rebates, returns and promotions                                                            |            | 17,539        |            | 16,001            |            |            |            |            |             |             |             |             |             |             |
| Accrued compensation and employee related obligations                                              |            | 2,843         |            | 3,993             |            |            |            |            |             |             |             |             |             |             |
| Accrued taxes on income (Note 5)                                                                   |            | 4,309         |            | 2,993             |            |            |            |            |             |             |             |             |             |             |
|                                                                                |            |               |            |                   |            |            |            |            |             |             |             |             |             |             |
| Total current liabilities                                                                          |            | 53,933        |            | 46,282            |            |            |            |            |             |             |             |             |             |             |
| Long-term debt (Note 4)                                                                            |            | 31,636        |            | 25,881            |            |            |            |            |             |             |             |             |             |             |
| Deferred taxes on income (Note 5)                                                                  |            | 2,635         |            | 3,193             |            |            |            |            |             |             |             |             |             |             |
| Employee related obligations (Note 6)                                                              |            | 6,919         |            | 7,149             |            |            |            |            |             |             |             |             |             |             |
| Long-term taxes payable (Note 5)                                                                   |            | 341           |            | 2,881             |            |            |            |            |             |             |             |             |             |             |
| Other liabilities                                                                                |            | 14,086        |            | 13,398            |            |            |            |            |             |             |             |             |             |             |
|                                                                                |            |               |            |                   |            |            |            |            |             |             |             |             |             |             |
| Total liabilities                                                                                |            | $109,550      |            | 98,784            |            |            |            |            |             |             |             |             |             |             |
| Commitments and Contingencies (Note 11)                                                            |            |               |            |                   |            |            |            |            |             |             |             |             |             |             |
| Shareholders’ equity:                                                                              |            |               |            |                   |            |            |            |            |             |             |             |             |             |             |
| Common stock — par value $1.00per share (authorized4,320,000,000shares; issued3,119,843,000shares) |            | $3,120        |            | 3,120             |            |            |            |            |             |             |             |             |             |             |
| Accumulated other comprehensive income (loss) (Note 7)                                             |            | (11,253)      |            | (12,527)          |            |            |            |            |             |             |             |             |             |             |
| Retained earnings and Additional paid-in capital                                                   |            | 155,360       |            | 153,843           |            |            |            |            |             |             |             |             |             |             |
| Less: common stock held in treasury, at cost (712,997,000and712,765,000shares)                     |            | 75,689        |            | 75,662            |            |            |            |            |             |             |             |             |             |             |
| Total shareholders’ equity                                                                         |            | $71,538       |            | 68,774            |            |            |            |            |             |             |             |             |             |             |
| Total liabilities and shareholders’ equity                                                         |            | $181,088      |            | 167,558           |            |            |            |            |             |             |             |             |             |             |

---

| Column 1                                                                                | Column 2   | Column 3                | Column 4   | Column 5    | Column 6   | Column 7   | Column 8   | Column 9   | Column 10   | Column 11   | Column 12   | Column 13   | Column 14   | Column 15   |
|:------------------------------------------------------------------------------------------|:-----------|:------------------------|:-----------|:------------|:-----------|:-----------|:-----------|:-----------|:------------|:------------|:------------|:------------|:------------|:------------|
|                                                                                |            |                         |            |             |            |            |            |            |             |             |             |             |             |             |
|                                                                                |            | Fiscal Six Months Ended |            |             |            |            |            |            |             |             |             |             |             |             |
|                                                                                |            | June 30,2024            |            | July 2,2023 |            |            |            |            |             |             |             |             |             |             |
| Cash flows from operating activities                                                      |            |                         |            |             |            |            |            |            |             |             |             |             |             |             |
| Net earnings                                                                              |            | $7,941                  |            | 5,076       |            |            |            |            |             |             |             |             |             |             |
| Adjustments to reconcile net earnings to cash flows from operating activities:            |            |                         |            |             |            |            |            |            |             |             |             |             |             |             |
| Depreciation and amortization of property and intangibles                                 |            | 3,597                   |            | 3,814       |            |            |            |            |             |             |             |             |             |             |
| Stock based compensation                                                                  |            | 643                     |            | 688         |            |            |            |            |             |             |             |             |             |             |
|                                                                                |            |                         |            |             |            |            |            |            |             |             |             |             |             |             |
|                                                                                |            |                         |            |             |            |            |            |            |             |             |             |             |             |             |
| Asset write-downs                                                                         |            | 379                     |            | 388         |            |            |            |            |             |             |             |             |             |             |
|                                                                                |            |                         |            |             |            |            |            |            |             |             |             |             |             |             |
|                                                                                |            |                         |            |             |            |            |            |            |             |             |             |             |             |             |
|                                                                                |            |                         |            |             |            |            |            |            |             |             |             |             |             |             |
| Net gain on sale of assets/businesses                                                     |            | (223)                   |            | (47)        |            |            |            |            |             |             |             |             |             |             |
|                                                                                |            |                         |            |             |            |            |            |            |             |             |             |             |             |             |
| Deferred tax provision                                                                    |            | (2,257)                 |            | (2,342)     |            |            |            |            |             |             |             |             |             |             |
| Credit losses and accounts receivable allowances                                          |            | —                       |            | —           |            |            |            |            |             |             |             |             |             |             |
| Changes in assets and liabilities, net of effects from acquisitions and divestitures:     |            |                         |            |             |            |            |            |            |             |             |             |             |             |             |
| Increase in accounts receivable                                                           |            | (1,163)                 |            | (599)       |            |            |            |            |             |             |             |             |             |             |
| Increase in inventories                                                                   |            | (739)                   |            | (741)       |            |            |            |            |             |             |             |             |             |             |
| Increase/(Decrease) in accounts payable and accrued liabilities                           |            | 449                     |            | (1,061)     |            |            |            |            |             |             |             |             |             |             |
| Decrease/(Increase) in other current and non-current assets                               |            | 3,731                   |            | (1,144)     |            |            |            |            |             |             |             |             |             |             |
| (Decrease)/Increase in other current and non-current liabilities                          |            | (3,068)                 |            | 3,407       |            |            |            |            |             |             |             |             |             |             |
|                                                                                |            |                         |            |             |            |            |            |            |             |             |             |             |             |             |
| Net cash flows from operating activities                                                  |            | 9,290                   |            | 7,439       |            |            |            |            |             |             |             |             |             |             |
|                                                                                |            |                         |            |             |            |            |            |            |             |             |             |             |             |             |
| Cash flows from investing activities                                                      |            |                         |            |             |            |            |            |            |             |             |             |             |             |             |
| Additions to property, plant and equipment                                                |            | (1,783)                 |            | (1,987)     |            |            |            |            |             |             |             |             |             |             |
| Proceeds from the disposal of assets/businesses, net (Note 10)                            |            | 573                     |            | 116         |            |            |            |            |             |             |             |             |             |             |
| Acquisitions, net of cash acquired (Note 10)                                              |            | (14,807)                |            | —           |            |            |            |            |             |             |             |             |             |             |
| Purchases of investments                                                                  |            | (1,184)                 |            | (9,688)     |            |            |            |            |             |             |             |             |             |             |
| Sales of investments                                                                      |            | 1,706                   |            | 11,877      |            |            |            |            |             |             |             |             |             |             |
| Credit support agreements activity, net                                                   |            | 1,430                   |            | (798)       |            |            |            |            |             |             |             |             |             |             |
| Other (including capitalized licenses and milestones)                                     |            | (86)                    |            | 19          |            |            |            |            |             |             |             |             |             |             |
|                                                                                |            |                         |            |             |            |            |            |            |             |             |             |             |             |             |
| Net cash used by investing activities                                                     |            | (14,151)                |            | (461)       |            |            |            |            |             |             |             |             |             |             |
|                                                                                |            |                         |            |             |            |            |            |            |             |             |             |             |             |             |
| Cash flows from financing activities                                                      |            |                         |            |             |            |            |            |            |             |             |             |             |             |             |
| Dividends to shareholders                                                                 |            | (5,854)                 |            | (6,034)     |            |            |            |            |             |             |             |             |             |             |
| Repurchase of common stock                                                                |            | (1,611)                 |            | (3,918)     |            |            |            |            |             |             |             |             |             |             |
| Proceeds from short-term debt                                                             |            | 13,976                  |            | 12,221      |            |            |            |            |             |             |             |             |             |             |
| Repayment of short-term debt                                                              |            | (3,915)                 |            | (13,611)    |            |            |            |            |             |             |             |             |             |             |
| Proceeds from long-term debt, net of issuance costs                                       |            | 6,659                   |            | 7,674       |            |            |            |            |             |             |             |             |             |             |
| Repayment of long-term debt                                                               |            | (803)                   |            | (501)       |            |            |            |            |             |             |             |             |             |             |
| Proceeds from the exercise of stock options/employee withholding tax on stock awards, net |            | 290                     |            | 254         |            |            |            |            |             |             |             |             |             |             |
| Credit support agreements activity, net                                                   |            | 281                     |            | (126)       |            |            |            |            |             |             |             |             |             |             |
|                                                                                |            |                         |            |             |            |            |            |            |             |             |             |             |             |             |
| Settlement of convertible debt acquired from Shockwave                                    |            | (970)                   |            |             | —          |            |            |            |             |             |             |             |             |             |
| Proceeds from Kenvue initial public offering                                              |            | —                       |            | 4,241       |            |            |            |            |             |             |             |             |             |             |
|                                                                                |            |                         |            |             |            |            |            |            |             |             |             |             |             |             |
| Other                                                                                |            | 37                      |            | (53)        |            |            |            |            |             |             |             |             |             |             |
|                                                                                |            |                         |            |             |            |            |            |            |             |             |             |             |             |             |
| Net cash flows from financing activities                                                  |            | 8,090                   |            | 147         |            |            |            |            |             |             |             |             |             |             |

---

| Column 1                                                               | Column 2   | Column 3                    | Column 4   | Column 5        | Column 6   | Column 7    | Column 8   | Column 9        | Column 10   | Column 11   | Column 12   | Column 13   | Column 14   | Column 15   | Column 16   | Column 17   | Column 18   | Column 19   | Column 20   | Column 21   | Column 22   | Column 23   | Column 24   | Column 25   | Column 26   | Column 27   |
|:-----------------------------------------------------------------------|:-----------|:----------------------------|:-----------|:----------------|:-----------|:------------|:-----------|:----------------|:------------|:------------|:------------|:------------|:------------|:------------|:------------|:------------|:------------|:------------|:------------|:------------|:------------|:------------|:------------|:------------|:------------|:------------|
|                                                                        |            |                             |            |                 |            |             |            |                 |             |             |             |             |             |             |             |             |             |             |             |             |             |             |             |             |             |             |
|                                                                        |            | Fiscal Second Quarter Ended |            |                 |            |             |            |                 |             |             |             |             |             |             |             |             |             |             |             |             |             |             |             |             |             |             |
|                                                                        |            | June 30,2024                |            | Percentto Sales |            | July 2,2023 |            | Percentto Sales |             |             |             |             |             |             |             |             |             |             |             |             |             |             |             |             |             |             |
| Sales to customers (Note 9)                                            |            | $22,447                     |            | 100.0           | %          |             | $21,519    |                 | 100.0       | %           |             |             |             |             |             |             |             |             |             |             |             |             |             |             |             |             |
| Cost of products sold                                                  |            | 6,869                       |            |                 | 30.6       |             |            | 6,462           |             | 30.0        |             |             |             |             |             |             |             |             |             |             |             |             |             |             |             |             |
| Gross profit                                                           |            | 15,578                      |            |                 | 69.4       |             |            | 15,057          |             | 70.0        |             |             |             |             |             |             |             |             |             |             |             |             |             |             |             |             |
| Selling, marketing and administrative expenses                         |            | 5,681                       |            |                 | 25.3       |             |            | 5,396           |             | 25.1        |             |             |             |             |             |             |             |             |             |             |             |             |             |             |             |             |
| Research and development expense                                       |            | 3,440                       |            |                 | 15.3       |             |            | 3,703           |             | 17.2        |             |             |             |             |             |             |             |             |             |             |             |             |             |             |             |             |
| In-process research and development impairments                        |            | 194                         |            |                 | 0.9        |             |            | —               |             | —           |             |             |             |             |             |             |             |             |             |             |             |             |             |             |             |             |
| Interest income                                                        |            | (395)                       |            |                 | (1.8)      |             |            | (326)           |             | (1.5)       |             |             |             |             |             |             |             |             |             |             |             |             |             |             |             |             |
| Interest expense, net of portion capitalized                           |            | 270                         |            |                 | 1.2        |             |            | 217             |             | 1.0         |             |             |             |             |             |             |             |             |             |             |             |             |             |             |             |             |
| Other (income) expense, net                                            |            | 653                         |            |                 | 2.9        |             |            | (384)           |             | (1.8)       |             |             |             |             |             |             |             |             |             |             |             |             |             |             |             |             |
| Restructuring (Note 12)                                                |            | (13)                        |            |                 | 0.0        |             |            | 145             |             | 0.7         |             |             |             |             |             |             |             |             |             |             |             |             |             |             |             |             |
| Earnings before provision for taxes on income                          |            | 5,748                       |            |                 | 25.6       |             |            | 6,306           |             | 29.3        |             |             |             |             |             |             |             |             |             |             |             |             |             |             |             |             |
| Provision for taxes on income (Note 5)                                 |            | 1,062                       |            |                 | 4.7        |             |            | 930             |             | 4.3         |             |             |             |             |             |             |             |             |             |             |             |             |             |             |             |             |
| Net earnings from continuing operations                                |            | 4,686                       |            |                 | 20.9       | %           |            | 5,376           |             | 25.0        | %           |             |             |             |             |             |             |             |             |             |             |             |             |             |             |             |
| Net earnings (loss) from discontinued operations, net of tax (Note 13) |            | —                           |            |                 |            |             | (232)      |                 |             |             |             |             |             |             |             |             |             |             |             |             |             |             |             |             |             |             |
| Net earnings                                                           |            | $4,686                      |            |                 |            |             | $5,144     |                 |             |             |             |             |             |             |             |             |             |             |             |             |             |             |             |             |             |             |
| Net earnings (loss) per share (Note 8)                                 |            |                             |            |                 |            |             |            |                 |             |             |             |             |             |             |             |             |             |             |             |             |             |             |             |             |             |             |
| Continuing operations - basic                                          |            | $1.95                       |            |                 |            |             | $2.07      |                 |             |             |             |             |             |             |             |             |             |             |             |             |             |             |             |             |             |             |
| Discontinued operations - basic                                        |            | —                           |            |                 |            |             | (0.09)     |                 |             |             |             |             |             |             |             |             |             |             |             |             |             |             |             |             |             |             |
| Total net earnings (loss) per share - basic                            |            | $1.95                       |            |                 |            |             | $1.98      |                 |             |             |             |             |             |             |             |             |             |             |             |             |             |             |             |             |             |             |
| Continuing operations - diluted                                        |            | $1.93                       |            |                 |            |             | $2.05      |                 |             |             |             |             |             |             |             |             |             |             |             |             |             |             |             |             |             |             |
| Discontinued operations - diluted                                      |            | —                           |            |                 |            |             | (0.09)     |                 |             |             |             |             |             |             |             |             |             |             |             |             |             |             |             |             |             |             |
| Total net earnings (loss) per share - diluted                          |            | $1.93                       |            |                 |            |             | $1.96      |                 |             |             |             |             |             |             |             |             |             |             |             |             |             |             |             |             |             |             |
| Avg. shares outstanding                                                |            |                             |            |                 |            |             |            |                 |             |             |             |             |             |             |             |             |             |             |             |             |             |             |             |             |             |             |
| Basic                                                                  |            | 2,406.8                     |            |                 |            |             | 2,598.4    |                 |             |             |             |             |             |             |             |             |             |             |             |             |             |             |             |             |             |             |
| Diluted                                                                |            | 2,422.0                     |            |                 |            |             | 2,625.7    |                 |             |             |             |             |             |             |             |             |             |             |             |             |             |             |             |             |             |             |

---

English News:
**Johnson & Johnson Reports Mixed Results Amid Inventory Challenges, While Pinnacle Financial Partners Expands in Florida** In a recent financial update, Johnson & Johnson reported mixed results for the second quarter of 2024. The company faced inventory issues within its Vision segment, particularly affecting the contact lens business, which led to a 1.2% sales decline in the U.S. Despite these challenges, Johnson & Johnson demonstrated resilience, with the company citing a sequential improvement over the quarter. By June 30, 2024, sales had returned to historical levels, indicating a rebound in its Vision business. Overall, Johnson & Johnson posted a solid performance across its portfolio. The healthcare giant announced a 6.5% increase in total adjusted sales, reaching $22.4 billion for the quarter. Additionally, adjusted earnings per share saw an uptick of $0.26, culminating in $2.82. These figures highlight the company's ability to sustain growth amidst operational hurdles within specific segments. In another notable development, Pinnacle Financial Partners Inc. has successfully expanded its footprint in Florida by entering the Jacksonville market. The financial firm recently inaugurated its first two branches in the area. Within just three months of operations, Pinnacle Financial Partners reported $20.1 million in loans, $28.8 million in deposits, and an impressive $614.6 million in wealth management assets. This expansion marks a strategic move for Pinnacle, indicating robust growth potential in an emerging market. Both companies illustrate the dynamic nature of business operations, with Johnson & Johnson managing internal challenges while upholding overall growth, and Pinnacle Financial Partners leveraging market expansion to solidify its presence in a new region.

Chinese News:
跨国药企半年报出炉：强生暂领首位 阿斯利康同比增速最高 “药王”之争尚未落幕 截至7月31日，头部跨国药企中已经有至少9家公布了他们2024年Q2季度的财报，这也意味着各家上半年的营收情况基本浮出水面。 从目前公开的数据来看，强生以438.3亿美元的整体营收暂且排在首位，紧随其后的是罗氏和辉瑞，基本延续了2023年上半年全球药企TOP3的排名顺序。 此外，除了辉瑞业绩增速同比为负外，其余几家在2024年均实现了营收的同比正向增长，其中固定汇率下阿斯利康同比增速达到18%，诺华增速也超过了10%。而在2023年上半年，全球营收排名前十的跨国药企中有一半业绩增速为负，另一半也堪堪保持了个位数的增幅而已。 “海外药企正在复苏中，你可以注意下目前公布业绩的几家中，艾伯维、赛诺菲、阿斯利康、诺华等等，都调高了全年度业绩指引，大家对今年的业绩表现信心还是比较足的。”一位券商医药研究员对《华夏时报》记者表示。 “重磅炸弹”们业绩如何？ 对于跨国药企来说，每个财报季度的业绩数字涨跌背后，旗下“明星产品”的销量增速往往是最为关键的一环，也是市场最关心的表现之一。 2024年上半年，默沙东旗下新任“药王”Keytruda（帕博利珠单抗）销售额继续创新高，上半年贡献了142.17亿美元的营收，业绩同比增速为18%，充分验证了其布局多适应证策略的市场化优势，目前K药获批适应证数量已达到40个。 与此同时，随着专利到期，生物类似药纷纷上市，艾伯维旗下蝉联11年全球“药王”的修美乐Humira（阿达木单抗）在上半年营收仅为50.84亿美元，同比下滑了约32%。 从市场表现来看，艾伯维旗下Skyrizi（利生奇珠单抗）和Rinvoq（乌帕替尼）有望成为修美乐之后撑起艾伯维业绩的下一个“当家花旦”人选，两者在上半年分别实现了47.35亿美元和25.23亿美元的营收业绩，但同比增速达到46.6%和60.4%，增长势头不可谓不强劲。 不能忽略的是，手握“减肥神药”司美格鲁肽的诺和诺德同样有望冲击“药王”宝座。2023上半年，三款司美格鲁肽药物为诺和诺德创造了约91.68亿美元的销量数据，更令市场期待的是，在从降糖领域成功破圈到减重领域后，司美格鲁肽作为glp-1类产品的代表始终增速喜人。 不过目前全球两大糖尿病巨头诺和诺德和礼来都尚未公布相关业绩，也为2024年全球药企的销量排行榜暂时留下了一些悬念。 上半年销售额破50亿美元的产品列表中，赛诺菲的王牌产品度普利尤单抗在实现61.38亿欧元（约66.44亿美元）的基础上，同样实现了同比增长27.1%的增长速度，预计全年销售额在全球药品销售总榜上同样名列前茅。 销售额同样突破50亿美元的还有强生旗下两款超级大单品Stelara（乌司奴单抗）和Darzalex（达雷妥尤单抗），两者在上半年的营收分别为53.36亿美元和55.7亿美元，同比增速则为1.8%和18.6%。从市场表现来看，无论是销售额还是增速，发力肿瘤领域的达雷妥尤单抗都已超过了自免领域的乌司奴单抗。 肿瘤同样是阿斯利康的强势领域，2024年上半年其重磅产品奥希替尼（Tagrisso）营收表现为32.02亿美元，同比增速为13%。 财报中同样透露，阿斯利康负责销售的ADC“战神”DS-8201（Enhertu）在上半年实现总营收9.32亿美元，同比增长速度为62%，也是各大药企明星产品中增速非常亮眼的一款产品。 跨国药企在中国市场表现 伴随着战略调整、人事更迭以及越来越频繁的收并购和BD交易，中国市场和国内创新药在MNC的财报中出现频率也越来越高。 过去的半年时间里，跨国药企人事变动消息一直络绎不绝。强生中国区主席、强生医疗科技中国区总裁宋为群辞职，继任者周敏涛于7月25日上任，此外，强生多个业务高管相继离职向外寻找机会。诺华现肿瘤治疗领域负责人严琼离开，肿瘤治疗领域团队暂由诺华现零售、商务部负责人陈晖代管，GSK中国疫苗业务负责人冯碧霞离任。 高管的来或去除了个人选择外，多少跟公司的业务架构调整脱不开关系，2024年，跨国药企在华正面临着新的机遇和挑战。 在此次财报披露中，默沙东的HPV疫苗（GARDASIL/GARDASIL 9）销售额为24.8亿美元，同比仅增长1%，令市场哗然。 从2006年全球第一支HPV疫苗（默沙东4价）面世，到2020年万泰生物2价HPV疫苗正式投入市场。将近15年时间里，中国HPV疫苗市场一直由默沙东和GSK两大巨头二分天下。此次HPV疫苗在中国市场的销售额大幅下降，默沙东解释称中国市场销售额的下降主要是由于发货时间的问题，但市场和投资者显然并不满意这个答案。 财报显示，2024年上半年默沙东中国区收入为35.34亿美元，占其全球市场12.4%的份额。 总的来看，大多数跨国药企在中国市场的增速仍然保持着强劲的增长态势。得益于旗下多款抗癌药的销售增长，罗氏上半年在中国区实现营业收入为16.09亿瑞士法郎（约18.18亿美元），同比增长14%。 号称“最懂中国的跨国药企”阿斯利康中国市场上半年收入为33.78亿美元，同比增长15%。 诺华制药上半年在中国市场销售额为21亿美元，同比增长29%，是目前跨国药企中中国市场增速最快的一家。过去半年，诺华制药在中国的首个放射配体疗法生产基地落户浙江海盐，预计2026年建成投产。

Japanese News:
ジョンソン・エンド・ジョンソン（J&J）は、2024年第2四半期の決算を発表し、売上高と利益がウォール街の予想を上回る結果となりました。主な要因は、がん治療薬ダルザレックスや乾癬治療薬ステラーラなどの医薬品売上の好調さです。 売上高は224億ドルで、アナリスト予想の223億ドルをわずかに上回りました。調整後の利益は1株当たり2.82ドルとなり、予想の2.70ドルを超えました。ステラーラの売上高は前年同期比3.1％増の28.9億ドルで、予想の27.7億ドルを上回り、ダルザレックスの売上高は18.4％増の28.8億ドルで、アナリスト予想の28.6億ドルにほぼ一致しました。 2024年通期予想の上方修正 J&Jは、好調な業績を受けて2024年の総売上高見通しを上方修正しました。新たな予想では、売上高は892億ドルから896億ドルの範囲で、前回予想の887億ドルから891億ドルに比べて顕著な伸びを見込んでいます。しかし、1株当たりの年間予想は従来の10.60ドル～10.75ドルから、10ドル～10.10ドルに下方修正されました。この修正には、業績改善による5セントの増加と、最近の買収、特に心臓医療機器会社ショックウェーブの130億ドルでの買収に伴うコスト関連の68セント減が含まれています。 医療技術事業とM&A活動 J&Jの医療技術事業は、売上高が2.2％増の79億6,000万ドルとなりましたが、アナリスト予想の81億7,000万ドルを下回りました。今年、同社はM&A活動を活発に行っており、5月には総額21億ドルで実験的な皮膚疾患治療薬を買収しています。 ステラーラとダルザレックスの展望 ステラーラは、2025年にはバイオシミラー医薬品との競争に直面する見込みです。アナリストは、ステラーラの売上高が2024年に100億ドルを超えると予測しており、競合の影響で2025年には売上高が70億ドル程度に減少する可能性もあると考えています。しかし、J&JのCFOジョー・ウォルク氏は、ステラーラの2025年に向けた米国での保険適用を確保できるとの自信を示し、医薬品分野での成長に対する強いコミットメントを表明しています。 ダルザレックスは引き続き好調で、アナリストは今年の売上高が110億ドルを超えると予測しています。また、がん治療薬イムブルビカは前年同期比8.5％減少しましたが、売上高は7億7000万ドルで予想を上回りました。 新薬の進展と生産能力の増強 新薬であるカーヴィクティの売上高は1億8600万ドルで、予想の2億100万ドルをわずかに下回りましたが、前年を60％近く上回る成長を記録しました。J&Jは、ニュージャージーとベルギーにある施設でCarvyktiの生産能力を増強し、需要に応えるため積極的に取り組んでいます。

Spanish News:
Johnson & Johnson (J&J) ha anunciado un beneficio neto de 4.686 millones de dólares (4.301 millones de euros) en el segundo trimestre de 2024, lo que supone una caída del 8,9% en comparación con el mismo período del año anterior. Resultados clave del segundo trimestre: Ventas totales: 22.447 millones de dólares (20.605 millones de euros), un aumento del 4,3% en comparación con el año pasado. Negocio farmacéutico: Las ventas del segmento farmacéutico crecieron un 5,5%, alcanzando los 14.490 millones de dólares (13.301 millones de euros). MedTech: La división de tecnología médica (MedTech) registró un crecimiento del 2,2%, alcanzando los 7.957 millones de dólares (7.304 millones de euros). A pesar de la caída en el beneficio neto en el segundo trimestre, la compañía experimentó un fuerte desempeño en el primer semestre de 2024, con un beneficio neto de 7.941 millones de dólares (7.289 millones de euros), lo que representa un aumento del 62,6% en comparación con el mismo período de 2023. Las ventas del semestre aumentaron un 3,3%, alcanzando los 43.830 millones de dólares (40.234 millones de euros). Declaraciones: Joaquín Duato, presidente y CEO de Johnson & Johnson, destacó: "El desempeño de Johnson & Johnson en el segundo trimestre refleja nuestro incansable enfoque en avanzar en la próxima ola de innovación médica, lo que resultó en fuertes ventas y crecimiento de las ganancias operativas ajustadas por acción." Revisión de las previsiones para 2024: La compañía ha revisado al alza sus previsiones para el conjunto del ejercicio 2024, reflejando un mejor desempeño y el impacto de las adquisiciones recientes de Shockwave Medical, Proteologix y NM26 Bispecific Antibody. Ahora, Johnson & Johnson espera alcanzar ventas operacionales de 89.400 millones de dólares (82.065 millones de euros), frente a la previsión anterior de 88.900 millones de dólares (81.606 millones de euros). Además, J&J espera que su resultado operativo ajustado por acción sea de 10,05 dólares, un aumento frente a la estimación previa de 10,68 dólares.

Greek News:
Σημαντική κάμψη παρουσίασαν τα οικονομικά αποτελέσματα της Johnson & Johnson για το δεύτερο οικονομικό τρίμηνο του 2024, σύμφωνα με την επίσημη ανακοίνωση της εταιρείας. Τα καθαρά κέρδη ανήλθαν σε 4,686 δισεκατομμύρια δολάρια, σημειώνοντας μείωση κατά 8,9% σε σύγκριση με την αντίστοιχη περίοδο του 2023, όταν τα καθαρά κέρδη είχαν διαμορφωθεί στα 5,144 δισεκατομμύρια δολάρια. Παράλληλα, παρατηρείται υποχώρηση και στις δαπάνες για έρευνα και ανάπτυξη (R&D), οι οποίες μειώθηκαν στα 3.440 εκατομμύρια δολάρια, ή 15,3% των πωλήσεων. Το αντίστοιχο ποσό το δεύτερο τρίμηνο του 2023 ανερχόταν σε 3.703 εκατομμύρια δολάρια (17,2% των πωλήσεων), γεγονός που αντικατοπτρίζει τόσο απόλυτη όσο και σχετική μείωση της επένδυσης στην καινοτομία. Η εταιρεία κατέγραψε επίσης χρέωση ύψους 0,2 δισεκατομμυρίων δολαρίων σχετική με το βιοομοειδές M710, το οποίο αποκτήθηκε μέσω της εξαγοράς της εταιρίας Momenta το 2020. Το περιουσιακό αυτό στοιχείο έχει πλέον απομειωθεί πλήρως, μετά από επιπλέον απομείωση 0,2 δισεκατομμυρίων δολαρίων που είχε προηγηθεί το τρίτο τρίμηνο του 2023. Ανάλογα, το πρώτο εξάμηνο του 2023 η εταιρεία είχε καταγράψει χρέωση 0,1 δισεκατομμυρίων δολαρίων, που σχετιζόταν με την άυλη περιουσία υπό ανάπτυξη από την εξαγορά της εταιρίας Pulsar Vascular το 2016.

Question:
Are there any significant changes or irregularities in the amount of operating, investing and financing cash flow? Please quote the piece(s) of news aligned with the finding(s), if any.

Answer:

Question: Are there any significant changes or irregularities in the amount of operating, investing and financing cash flow? Please quote the piece(s) of news aligned with the finding(s), if any.